News & Perspective

Dec 31, 2008

Dec 31, 2008

Study hints at pneumonia risk with resistant flu viruses

(CIDRAP News) – A newly published analysis of oseltamivir-resistant influenza viruses collected last winter in Norway hints that they may increase an infected person's risk of pneumonia and sinus infections, but the small number of patients in the study means the finding is no more than a hint at this point.

Dec 19, 2008

Dec 19, 2008

With H1N1 resistance, CDC changes advice on flu drugs

(CIDRAP News) – Increased resistance to oseltamivir (Tamiflu), the leading influenza drug, has prompted federal health officials to change their advice about flu treatment, saying clinicians for now should consider using zanamivir (Relenza) or a combination of two drugs for patients suspected of having influenza A.

Dec 17, 2008

Dec 17, 2008

Cost, resistance aired in HHS webcast on antivirals

(CIDRAP News) – Cost issues and the risk of viral resistance drew considerable attention today in an online presentation by federal health officials on their revised guidance regarding use of antiviral drugs in an influenza pandemic.

The Department of Health and Human Services (HHS) released two guidance documents this week, one on antiviral use in general and one on employer stockpiling of antivirals.

Dec 12, 2008

Dec 12, 2008

CDC sees early-season signs of Tamiflu resistance

(CIDRAP News) – With this year's US influenza epidemic barely getting started, there are already signs of increased viral resistance to oseltamivir (Tamiflu), the most widely used antiviral drug, the Centers for Disease Control and Prevention (CDC) said today.

In its flu surveillance report for Nov 30 to Dec 6, released today, the CDC said 45 of 46 influenza A/H1N1 viruses tested so far have shown resistance to oseltamivir.

Sort Results By:

 Sort Results By:

Narrow results by:

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»